Archives
-
PBS Liposomes: Reliable Controls for Macrophage Depletion As
2026-06-18
This article details how PBS Liposomes (SKU K2722) deliver reproducible, inert controls for macrophage depletion workflows. Drawing on real laboratory scenarios, we analyze compatibility, optimization, and data interpretation challenges, demonstrating the value of APExBIO's PBS Liposomes for accurate, interpretable immunology assays.
-
AP20187: Chemical Inducer of Dimerization for Precise Gene C
2026-06-17
AP20187 is a synthetic, cell-permeable chemical inducer of dimerization engineered for controlled fusion protein activation in gene therapy and metabolic studies. Its high solubility, purity, and validated in vivo efficacy make it a benchmark reagent for conditional gene therapy activators. APExBIO provides AP20187 as a reliable, high-quality product for regulated cell signaling experiments.
-
Linarin from Herba Patriniae Induces Cell Cycle Arrest in NS
2026-06-17
This study identifies Linarin, a compound from Herba Patriniae, as an inducer of G0/G1 cell cycle arrest and cellular senescence in non-small-cell lung cancer (NSCLC) cells, mediated by downregulation of Cyclin A2/B1 and CHEK1. The findings suggest Linarin's potential as a novel therapeutic agent for NSCLC, with mechanistic insights supported by multi-modal assays.
-
Q-VD(OMe)-OPh: Elevating Translational Apoptosis Research
2026-06-16
This thought-leadership article explores the mechanistic depth and strategic utility of Q-VD(OMe)-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) for translational researchers. Integrating insights from recent cancer and neuroprotection studies, we discuss how this advanced pan-caspase inhibitor overcomes legacy limitations, supports complex assay design, and unlocks new experimental strategies. The article bridges rigorous scientific rationale with real-world protocol guidance, distinguishing itself from standard product write-ups by offering a roadmap for deploying Q-VD(OMe)-OPh at the cutting edge of apoptosis research.
-
Antimycin A4: ATP-Citrate Lyase Inhibitor for Metabolic Assa
2026-06-15
Antimycin A4 delivers dual inhibition of lipid biosynthesis and mitochondrial energy metabolism, enabling targeted, high-resolution research on cellular bioenergetics. This guide provides actionable protocols, troubleshooting strategies, and a translational perspective that leverages APExBIO’s trusted quality.
-
Cisplatin and Topotecan Regimens in First-Line SCLC Therapy
2026-06-13
This article examines the pivotal role of cisplatin-etoposide (PE) and emerging topotecan-based regimens in the first-line treatment of small cell lung cancer (SCLC). The reference study provides a detailed comparison of therapeutic efficacy, toxicity profiles, and evolving clinical strategies, highlighting key considerations for future cancer research and model design.
-
ATM Inhibition Promotes Macropinocytosis and Metabolic Adapt
2026-06-09
The reference study reveals that inhibiting ATM kinase induces macropinocytosis, enabling cancer cells to adapt metabolically and survive under nutrient-poor conditions. These findings highlight a metabolic vulnerability in ATM-inhibited tumors and provide new directions for research on DNA damage response inhibitors in cancer therapy.
-
3-Bromopyruvate and Cetuximab Overcome CRC Resistance via Fe
2026-06-09
This study demonstrates that combining 3-Bromopyruvate with cetuximab overcomes drug resistance in colorectal cancer cells by synergistically inducing autophagy-dependent ferroptosis and apoptosis. The work provides mechanistic insight into FOXO3a pathway restoration, with implications for therapeutic strategies targeting refractory metastatic colorectal cancer.
-
Optimizing Neurotoxicity Assays with Amyloid β-Peptide (1-42
2026-06-08
This article addresses common laboratory challenges in Alzheimer's disease research by examining reproducibility and interpretability in Aβ42 peptide neurotoxicity assays. Drawing on SKU B6057 from APExBIO, it delivers scenario-driven guidance for cell viability workflows, ion channel studies, and microglial activation models. Researchers can leverage these insights to ensure reliable and data-backed experimental outcomes.
-
Hippo Signaling Modules Shape Hepatobiliary Cell Fate and Ma
2026-06-05
This study uncovers how two distinct Hippo signaling modules, HPO1 and HPO2, regulate the differentiation and maturation of hepatocytes and cholangiocytes during mouse liver development. By integrating spatial transcriptomics and advanced imaging, the research offers new mechanistic insights with implications for liver regeneration and disease.
-
BV6 IAP Antagonist: Optimizing Apoptosis and Radiosensitizat
2026-06-03
BV6 stands out as a selective IAP antagonist that empowers researchers to drive apoptosis induction, radiosensitization, and disease modeling with reproducible precision. This guide details actionable protocols, advanced use-cases, and troubleshooting tips to maximize the scientific value of BV6 in cancer and endometriosis studies.
-
Wortmannin: Precision PI3K Inhibitor for Cancer and Viral Re
2026-06-02
Wortmannin enables researchers to dissect the PI3K/Akt/mTOR pathway with unparalleled specificity, facilitating robust workflows in cancer, apoptosis, and emerging antiviral models. Leveraging its nanomolar potency, this selective and irreversible PI3K inhibitor—supplied by APExBIO—supports advanced assay design and troubleshooting for both established and translational experimental paradigms.
-
Co-Targeting BRD4 and RAC1 Disrupts Oncogenic Axes in Breast
2026-06-02
This study demonstrates that combined inhibition of BET bromodomain BRD4 and RAC1 signaling suppresses growth, stemness, and tumorigenesis across molecular subtypes of breast cancer. Mechanistically, the approach disrupts the c-MYC-G9a-FTH1 axis and downregulates HDAC1, highlighting novel epigenetic vulnerabilities with translational potential.
-
Q-VD-OPh: Decoding Caspase Inhibition in Apoptosis Assays
2026-06-01
Explore how Q-VD-OPh, a potent pan-caspase inhibitor, enables precise dissection of apoptosis signaling and pore formation dynamics in advanced research models. This article uniquely connects super-resolution mitochondrial studies to practical assay design.
-
Calpain Inhibitor I, ALLN: Technical Guidance for Research U
2026-05-30
Calpain Inhibitor I (ALLN) is a potent, selective inhibitor for calpain and cathepsin proteases, enabling precise modulation of proteolytic activity in apoptosis assays and ischemia-reperfusion injury models. It is not suitable for diagnostic or medical applications and requires strict handling to maintain activity and minimize off-target effects.
446 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page